← All workflows

Clinical Trial Investigator Agreement

Draft Investigator Agreements in Minutes, Not Hours

14 minutes with CaseMark

Fast lane

We have it from here.

Choose the fast one-off run here, or jump into the workspace when you want saved history, revisions, and a fuller matter workflow.

Run this once here

Best for a quick one-off job. Add your email, upload the files, and we'll run the workflow and send the result to your inbox.

1. Add your email so we know where to send the result.

2. Upload the files you want analyzed.

3. Run the workflow and we'll take it from there.

Use in Workspace

Best for ongoing matters

Save and reopen matters, keep documents together, refine the output, rerun with changes, and export or share polished work product when you're done.

Open in Workspace

Need more context?

Scroll for the workflow details below if you want to review what this run handles, what documents help, and what the output looks like.

If this is part of a live matter, the workspace is the better fit: you can keep your documents together, revisit the result, and keep working without starting from scratch.

Jump to detailsOpen in Workspace

Start here

Run this workflow now

Best for a fast one-off run. Add your email, upload the files, and we'll deliver the result without sending you into the full app.

Workflow

Clinical Trial Investigator Agreement

Step 1 · Deliver to

Step 3 · Run this workflow

Workflow

Clinical Trial Investigator Agreement

Overview

CaseMark's Clinical Trial Investigator Agreement skill uses AI to draft comprehensive, FDA-compliant agreements between sponsors or CROs and principal investigators or institutions for regulated drug, biologic, and device studies. The tool automates regulatory cross-referencing across 21 CFR, ICH GCP, HIPAA, and IRB requirements while structuring payment, IP, publication, indemnity, and audit provisions tailored to each site's legal and institutional context.

Drafting clinical trial investigator agreements manually requires painstaking cross-referencing of FDA regulations, ICH GCP guidelines, HIPAA requirements, IRB obligations, and state-specific laws. Legal teams spend hours ensuring payment structures pass FMV and Anti-Kickback scrutiny, while negotiating indemnity terms that vary dramatically between academic medical centers, public institutions, and private sites—all of which delays study activation and enrollment timelines.

CaseMark automates the entire drafting process by ingesting your protocol, site details, and budget terms, then generating a fully structured investigator agreement with every required regulatory provision. The AI cross-references 21 CFR Parts 50, 54, 56, 312/812, ICH GCP E6(R2), HIPAA, and 45 CFR 46, producing a compliance-verified agreement with tailored exhibits—ready for review and execution in a fraction of the traditional timeline.

How it works

  1. 1. Upload your protocol, investigator's brochure, site details, PI credentials, and budget terms

  2. 2. AI identifies the regulatory track (drug/biologic vs. device) and drafts a fully structured investigator agreement

  3. 3. Review the agreement with built-in compliance checks against FDA, GCP, HIPAA, and IRB requirements

  4. 4. Export the finalized agreement and exhibits in your preferred format (DOCX, PDF)

What you get

  • Parties and Definitions

  • Study Description and Protocol Incorporation

  • Regulatory Obligations (FDA, IRB, GCP, HIPAA)

  • Investigational Product Handling and Accountability

  • Informed Consent and Vulnerable Population Provisions

  • Financial Disclosure and FMV/AKS Payment Compliance

  • Data Ownership, Publication Rights, and IP Provisions

  • Confidentiality and Data Integrity

  • Indemnification, Insurance, and Liability

  • Audit and Monitoring Access

  • Term, Termination, and Survival

  • Exhibits (Protocol, Budget, Delegation Log, Consent Forms)

  • Regulatory Compliance Checklist

What it handles

  • Automatic regulatory track detection for drug/biologic (21 CFR 312) vs. device (21 CFR 812) studies

  • Built-in compliance checks for FDA, ICH GCP E6(R2), HIPAA, and IRB requirements

  • FMV/Anti-Kickback Statute payment compliance and budget structuring

  • Publication rights, IP ownership, and data integrity provisions

  • Indemnification, insurance, and audit access clauses tailored to site type

  • Exhibit generation for protocol, budget, delegation log, and consent forms

Required documents

  • Study Protocol and Investigator's Brochure

    The clinical trial protocol (with number, title, version, phase, endpoints, and enrollment target) and the investigator's brochure or device manual

    .pdf, .docx

  • Site and PI Information

    Site legal name, state jurisdiction, institutional policies, PI credentials, sub-investigator details, and any required template language

    .pdf, .docx

  • Budget and Payment Terms

    Proposed budget model (per subject, per visit, milestones), payment schedule, invoicing rules, and financial disclosure information

    .pdf, .docx, .xlsx

Supporting documents

  • IRB Approval and Consent Forms

    IRB approval letters, informed consent/assent forms, recruitment materials, and vulnerable population plans

    .pdf, .docx

  • Insurance and Indemnity Documentation

    Certificates of insurance, institutional indemnity policies, sovereign immunity documentation, or academic liability caps

    .pdf, .docx

  • Existing Template or Institutional Agreement

    Any institutional master agreement, required template language, or prior investigator agreement to incorporate

    .pdf, .docx

Why teams use it

Eliminate hours of manual regulatory cross-referencing with automated compliance mapping across FDA, GCP, HIPAA, and IRB frameworks

Reduce legal risk with built-in FMV/Anti-Kickback Statute payment compliance and financial disclosure provisions

Adapt agreements instantly for academic, public, or private sites with tailored indemnity and insurance language

Accelerate study start-up timelines by generating complete, exhibit-ready agreements in minutes

Questions

Does this handle both drug/biologic and device clinical trials?

Yes. CaseMark automatically detects whether your study falls under 21 CFR Part 312 (drugs/biologics with IND) or 21 CFR Part 812 (devices with IDE) and tailors every regulatory obligation accordingly.

How does CaseMark ensure payment terms comply with Anti-Kickback Statute and fair market value requirements?

CaseMark structures payment provisions to align with FMV principles and AKS safe harbors, flagging per-subject, per-visit, and milestone payment models for compliance review. The output includes language designed to withstand regulatory scrutiny.

Can I use this for academic medical centers and public institutions with indemnity limitations?

Absolutely. CaseMark adapts indemnification and insurance clauses to account for sovereign immunity, academic institutional caps, and other constraints common to public entities and university-affiliated sites.

What regulatory frameworks does the generated agreement cover?

The agreement addresses 21 CFR Parts 50, 54, 56, 312/812, ICH GCP E6(R2), HIPAA, 45 CFR 46 (including Subparts B, C, D for vulnerable populations), and applicable state privacy laws. CaseMark includes a compliance checklist so you can verify coverage.

Does the output include exhibits and ancillary documents?

Yes. CaseMark generates the core agreement along with exhibit frameworks for the protocol, budget and payment schedule, delegation of authority log, financial disclosure forms, and consent/assent form references, all incorporated by reference.

How long does it take to generate a complete investigator agreement?

CaseMark typically produces a comprehensive, compliance-checked investigator agreement in approximately 12–15 minutes, compared to the hours or days traditionally required for manual drafting and regulatory cross-referencing.

Related

Access and Indemnity Agreement (Due Diligence)

Draft Property Access Agreements in Minutes with AI

Access Indemnity Agreement

Draft Access & Indemnity Agreements in Minutes

Ad Fund Agreement

Draft Ad Fund Agreements in Minutes, Not Hours